The FDA Modernization Act 3.0
*(H.R. 7248)*

The FDA Modernization Act 2.0 (FDAMA 2.0) was enacted into law as Sec. 3209 of the Consolidated Appropriations Act, 2023, which President Biden signed on Dec. 29, 2022. FDAMA 2.0 lifted a mandate in the Federal Food, Drug, and Cosmetic Act (FDCA) that required animal testing of investigational new drugs (INDs) to establish safety and efficacy prior to clinical trials in humans.

FDAMA 2.0 did not ban animal testing, but it offered drug sponsors the option to use 21st century alternatives such as cell-based assays, organ chips, computer modeling, and bioprinting. The goal was not only to make drug testing more humane, speed drug development by reducing the attrition rate, since non-animal methods are typically superior predictors of human responses to drugs. An astonishing 90-95% of drugs that pass animal tests go on to fail in human clinical trials, wasting precious time for patients.

Over 7,000 rare diseases affect between 25-35 million Americans—and 95% of those diseases have no cure. Rare-disease patients stand to benefit substantially by the acceptance of non-animal methods because the poor reliability of animal models compounds high R&D costs to disincentivize investment in this area. The innovative 21st century methods outlined in FDAMA 2.0 are among the most promising frontiers in understanding rare diseases: organ chips for Barth Syndrome, 3D models (organoids) of the midbrain for NGLY1 deficiency (a rare neurological disease), and artificial intelligence (AI) in developing treatments for Fragile-X syndrome. As a 2022 article noted of Fragile-X, “[t]his is a disease for which there were no mouse models. A different approach was needed, and the patients-on-a-chip model, combined with AI, seemed to be the best solution.”

**The Problem**

To date, the FDA has not updated its regulations to conform with the law Congress passed in 2022. Dozens of FDA regulations continue to call for animal tests without offering drug sponsors any other option. FDA programs that qualify non-animal test methods are cursory, ineffective, and lack transparency.

**The Solution**

To effectuate the will of Congress, the FDA Modernization Act 3.0 would:

- Require the FDA to publish a final rule to fully implement FDAMA 2.0.
- Require the HHS Secretary to establish a process to qualify test methods to reduce or
replace animal tests. The new methods must either 1) improve test predictivity for safety and efficacy or 2) reduce development time for drugs and/or biologics.

- Require the HHS Secretary to hold a public meeting of stakeholders to solicit input about the qualification process for non-animal methods. After this public meeting, the FDA must propose guidance, provide a comment period, and finalize the guidance within a year of comments closing.

- Require the FDA to publish an annual report on its website analyzing the success of the qualification process, including an estimate of the number of animals saved by it.

---


1 See 21 C.F.R. §§ 312.22(c), 312.23(a)(3)(iv), 312.23(a)(5)(i), 312.23(a)(5)(ii), 312.23(a)(8), 312.23(a)(8)(i), 312.23(a)(8)(ii), 312.23(a)(10)(i), 312.23(a)(10)(ii), 312.33(a)(6), 312.8(a), 312.88, 312.160, 314.50(d)(2), 314.50(d)(2)(iv), 314.50(d)(5)(i), 314.50(d)(5)(vi)(a), 314.50(d)(5)(vi)(b), 314.93(e)(2), 315.6(d), 330.10(a)(2), 610.35(d), 812.2(c), 812.5(c), 812.27(a), 812.35(a)(3)(iii), 860.5(f), and 860.7(d)(2). For uniformity and consistency, the following regulations should also be updated: 21 C.F.R. §§ 3.7, 10.20, 14.95, 16.1, 50.24, 58.3, 201.56, 201.57, 201.1, 312.32, 312.160, 314.81, 314.430, 316.20, 330.14, 343.80, and 361.1. Definitions sections in the following regulations also must be harmonized with Sec. 3209 of the Consolidated Appropriations Act, 2023, P.L. 117-328, 136 Stat. 5822 (2022): 21 C.F.R. §§ 310.3, 312.3, 314.3, 315.2, 601.31, 812.3, and 860.3.